Phase I Safety and Pharmacokinetic Study of SU-014813 in Combination with Docetaxel in Patients with Advanced Solid Tumors

    May 2011 in “ European Journal of Cancer ”
    Maja J.A. de Jonge, Herlinde Dumez, Jos Kitzen … Patrick Schöffski
    Studysummary This phase I study determined that a combination of oral SU-014813 and docetaxel is a feasible treatment with a manageable safety profile and potential anti-tumor activity, particularly noted in melanoma and GIST patients.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on ejcancer.com →
    Discuss this study in the Community →